Objective: To study the clinical efficacy of modified Bazhentang combined with radiotherapy and chemotherapy in treating middle and advanced cervical cancer and investigate its effect on T cell subset

serum tumor markers and survival period. Method: The 177 patients with middle and advanced cervical cancer in our hospital from February 2009 to May 2012

were selected and divided into treatment group (89 cases) and control group (88 cases) according to the random number table. Patients in two groups were treated with radiotherapy and chemotherapy

while the patients in treatment received additional modified Bazhentang. Then the short-term efficacy

T cell subset

serum tumor markers and survival period of the two groups were compared. Result: The total effective rate was 87.64% in treatment group

better than 73.86% in control group (P<0.05). After the treatment

the levels of CD3+

CD4+ and CD4+/CD8+ were significantly increased in both groups

but the level of CD8+was significantly decreased (P<0.05). After the treatment

the levels of CD3+

CD4+ and CD4+/CD8+ in treatment group were significantly higher than those in control group

while the level of CD8+ was significantly lower than that of control group (P<0.05). The expression levels of carbohydrate antigen 125 (CA125)

squamous cell carcinoma associated antigen (SCCA) and carcino-embryonic antigen (CEA) were significantly decreased in both groups after treatment

and the decrease was more obvious in treatment group (P<0.05). The 1

2

3

5-year survival rate was 91.01%

55.06%

26.97%

13.48% respectively in treatment group

higher than 73.86%

32.95%

9.09%

3.41% in control group (P<0.05). Conclusion: Modified Bazhentang can significantly improve the immunity

reduce the level of serum tumor markers and prolong the survival time of the patients

so it has positive therapeutic effect on middle and advanced cervical cancer.